Don't Look Now: Nasdaq Profile (NTRB) Has Multiple Triggered Technicals (Low Float)

Able to soak in the day my latest breakout idea put together this past Thursday?

*Sponsored by Nutriband Inc. Don't Look Now: Nasdaq Profile (NTRB) Has Multiple Triggered Technicals (Low Float)  June 1st Greetings Readers, Able to soak in the day my latest breakout idea put together this past Thursday? Woof. Strap in. Brought into focus around 8:00AM EST, the low float Nasdaq idea absolutely kicked it into overdrive, making a vertical chart run in barely no time at all. From an approximate valuation of $3.50 around that 8:00AM EST jump-off, our Nasdaq profile erupted, hitting a high of $8.80 in pre-market. With a $5.50+ move in its pocket, my most recent champ blazed its way to a surge of approx. 151%. While that rocket was rocketing, a former breakout idea popped up on my screen. With a low float under 5Mn shares, an analyst $13 target suggesting significant upside potential, and a multitude of triggered technical indicators, it may be the perfect time to consider this Nasdaq profile for your watchlist. Oh, and as I mentioned above, this little firecracker rattled off an incredible two-day move of $7.50+ in January after one of my alerts. Now, that's not to say any move will happen like that again, but with all the potential catalysts shared above, now could be the time to consider taking a look at: *Nutriband Inc. (Nasdaq: NTRB)* Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse-deterrent fent-a-nyl patch incorporating their AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. And based on several potential breakout catalysts, NTRB has once again risen to the top spot on my watchlist: #1. A $13 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. Multiple Triggered Technical Indicators May Suggest A Positive Outlook And Trend Confirmation. #4. NTRB Continues To Create A Competitive Advantage By Protecting Critical IP With Key Patent. #5. A New Partnership To Leverage Visibility For Company's AI Tape And Other Key Brands. But more on those in a second... Full Company Breakdown: Nutriband Inc. (Nasdaq: NTRB) Nutriband Inc. is a pharmaceutical company with a specific focus on transdermal technologies. Their model is to apply Transdermal Tech to existing FDA approved drugs with a goal to improve safety, efficacy, patient comfort and more. The company's first product and lead platform technology is AVERSA, an abuse deterrent tech which is applicable to any patch on the market today. According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. The company has 2 revenue generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical along with Active Intelligence which specializes in sports recovery products. Nutriband is earning revenues to keep their development burn at a minimum. They also own their own manufacturing and clinical development capabilities which drastically reduces their costs for AVERSA and other technologies. Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids Upon approval of AVERSA™ fent-a-nyl, the company expects that the FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$800Mn in revenue. Aversa Pipeline Sources: NTRB Website. NTRB Presentation. ----- As mentioned above, NTRB has several potential catalysts that could create breakout buzz. Here's a few to consider now: #1. NTRB Potential Catalyst - A $13 Analyst Target Suggests Substantial Upside Potential! Back in the beginning of May, an analyst Noble Capital Markets reiterated a $13 target for NTRB. From NTRB's closing valuation this past Friday, that target suggested 100% potential upside. Here's some key report highlights: AVERSA Fent-a-nyl Margins Could Be Higher Than We Estimated. Our models for the AVERSA Fent-a-nyl abuse-deterrent patch have been based on margins comparable with its current products, plus a small premium over current generics. Our expected gross margin were between 40% and 50% in the initial years. The company announced the completion of a new evaluation to update its cost of goods estimates. It now believes it can achieve gross margins similar to newly-approved pharmaceutical products, which are typically in the range of 80% to 95% of the selling price. Conclusion. Nutriband continues to prepare for clinical testing, submission of regulatory approval filings, and commercial production for AVERSA Fent-a-nyl. With sufficient cash for the near term, we have pushed a st-ock offering from early FY2026 to late 2026, if necessary, and adjusted our FY2026 estimates. We are reiterating our Outperform rating and $13 price target. ----- #2. NTRB Potential Catalyst - A Low Float Could Create An Exceptionally Volatile Environment (Daily). According to info from the Yahoo Finance website, NTRB has a pretty low float. The website reports this profile to have roughly 4.41Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark? ----- #3. NTRB Potential Catalyst - Multiple Triggered Technical Indicators May Suggest A Positive Outlook And Trend Confirmation. On Friday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for NTRB. Here's their list (as of 4:00PM EST Friday): Short Term Indicators 20 Day Moving Average 20 - 50 Day MA Crossover 20 - 200 Day MA Crossover Medium Term Indicators 50 Day Moving Average 50 - 150 Day MA Crossover 50 - 200 Day MA Crossover Long Term Indicators 100 Day Moving Average 150 Day Moving Average 200 Day Moving Average 100 - 200 Day MA Crossover The website also shares its all-important "Trend Seeker" composite indicator is triggered as well. Make sure to watch these technical indicators closely moving forward. ----- #4. NTRB Potential Catalyst - NTRB Continues To Create A Competitive Advantage By Protecting Critical IP With Key Patent. Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded in Macao Official Bulletin No. 10 on March 5, 2025. Macao is a Special Administrative Region (SAR) of the People’s Republic of China that has its own patent system and patent laws which are separate and distinct from those of mainland China. The AVERSA™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia as well as two regions of China: Hong Kong and Macao. ... Read the full article here. ----- #5. NTRB Potential Catalyst - A New Partnership To Leverage Visibility For Company's AI Tape And Other Key Brands. UPDATE – Nutriband Signs Associate Partnership with Charlotte FC ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC. The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. “We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.’’ AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina. The Company also intends to use the relationship to promote its platform technology AVERSA and raise awareness for the technology which has the potential to be the World’s first and only abuse deterrent patch platform for managing chronic pain. Read the full article here. ----- (Nasdaq: NTRB) Potential Catalyst Recap - The Top 5 To Consider Right Now #1. A $13 Analyst Target Suggests Substantial Upside Potential! #2. A Low Float Could Create An Exceptionally Volatile Environment (Daily). #3. Multiple Triggered Technical Indicators May Suggest A Positive Outlook And Trend Confirmation. #4. NTRB Continues To Create A Competitive Advantage By Protecting Critical IP With Key Patent. #5. A New Partnership To Leverage Visibility For Company's AI Tape And Other Key Brands. ----- Coverage is officially reinitiated on Nutriband Inc. (Nasdaq: NTRB). I'll be in touch with updates when necessary. Talk again soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/01/2025 and ending on 06/02/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred twenty seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither SWN Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/ntrb-o1nsm/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice